Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 637-645

  Derosa, Giuseppe ^a   Gaddi, Antonio V ^b   Piccinni, Mario N ^a   Ciccarelli, Leonardina ^a   Salvadeo, Sibilla ^a   Peros, Emmanouil ^a   Ghelfi, Morena ^a   Ferrari, Ilaria ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antithrombotic effects; Combination therapy; Glimepiride metformin; Metabolic syndrome; Rosiglitazone metformin; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING TEST; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; FIBRINOLYSIS; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ITALY; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 18044390662     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.637.63587     Document Type: Article

References (42)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
2. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-7.
3. Abbott RD, Curb JD, Rodriguez BL, et al. Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. J Clin Epidemiol 2003;56:479-86.
4. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-9.
5. Theuma P, Fonseca VA. Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep 2003;3:248-54.
6. Liu S, Willett WC. Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 2002;4:454-61.
7. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002;90(5A):G19-26.
8. Tsikouris JP, Suarez JA, Meyerrose GE. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002;42:1187-99.
9. Grant P. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29(4 pt 2):44-52.
10. American Diabetes Association. Screening for diabetes [position statement]. Diabetes Care 2001;24:S21-4.
11. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, 3-5 June 1997. Geneva: World Health Organization, 1998.
12. World Health Organization-International Society of Hypertension. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines subcommittee. J Hypertens 1999;17:151-83.
13. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus [position statement]. Diabetes Care 2001;24:S44-7.
14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
15. Bunn HF, Gabbay HK, Gallop PM. The glycosylation of haemoglobin: relevance to diabetes mellitus. Science 1978;200:21-7.
16. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.
17. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6.
18. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992;2:427-38.
19. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1959;17:237-46.
20. Narayanan S. Preanalytical aspects of coagulation testing. Haematologica 1995;80:1-6.
21. Winer BJ. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill, 1971.
22. Fattah MA, Shaheen MH, Mahfouz MH. Disturbances of haemostasis in diabetes mellitus. Dis Markers 2003-2004;19:251-8.
23. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003;1:1575-9.
24. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
25. Alessi MC, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res 2000;32:504-8.
26. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-64.
27. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur 2004;97:673-8.
28. Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999;19:1582-7.
29. Garber AJ. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.
30. Derosa G, Cicero AFG, Mugellini A, et al. Long-term effect of thiazolidinediones on nonconventional cardiovascular risk factors: a randomized, double-blind clinical trial on patients affected by metabolic syndrome. Acta Diabetol, in press.
31. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108(suppl 6a):S15-22.
32. Vague P. Is metformin more than an oral hypoglycaemic agent? Diabet Metab 2003;29(6S):5-7.
33. Johnson JA, Simpson SH, Majumdar SR, Toth EL. Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8.
34. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;253:854-65.
35. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
36. McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother 2001;2:699-713.
37. Stumvoll M. Thiazolidinediones: some recent developments. Expert Opin Investig Drugs 2003;12:1179-87.
38. Camp HS. Thiazolidinediones in diabetes: current status and future outlook. Curr Opin Investig Drugs 2003;4:406-11.
39. Abbink EJ, Pickkers P, Jansen van Rosendaal A, et al. Vascular effects of glibenclamide vs glimepiride and metformin in type 2 diabetic patients. Diabet Med 2002;19:136-43.
40. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163-70.
41. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003;25:472-84.
42. Harte AL, McTernan PG, McTernan CL, Smith SA, Barnett AH, Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 2003;5:302-10.